Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.

Alsalim, Wathik; Persson, Margaretha; Ahrén, Bo

Alsalim, Wathik; Persson, Margaretha; Ahrén, Bo.

Affiliation

Alsalim W; Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Persson M; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Ahrén B; Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Diabetes Obes Metab ; 20(7): 1652-1658, 2018 07.

Article in En | MEDLINE | ID: mdl-29498469

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use; Glucagon/metabolism; Hypoglycemic Agents/therapeutic use; Metformin/therapeutic use; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use; Aged; Area Under Curve; Benzhydryl Compounds/therapeutic use; Blood Glucose/metabolism; Cross-Over Studies; Diabetes Mellitus, Type 2/metabolism; Female; Gastric Inhibitory Polypeptide/metabolism; Glucagon-Like Peptide 1/metabolism; Glucosides/therapeutic use; Glycated Hemoglobin/metabolism; Humans; Incretins/metabolism; Male; Middle Aged; Vildagliptin/therapeutic use

Key words

DPP-4 inhibition; SGLT-2 inhibition; dapagliflozin; glucagon; type 2 diabetes; vildagliptin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Glucagon / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Sodium-Glucose Transporter 2 Inhibitors / Hypoglycemic Agents / Metformin Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2018 Type: Article Affiliation country: Sweden

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google